Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity

• Lisa K. Brents,

  Affiliation Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Emily E. Reichard,

  Affiliation Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Sarah M. Zimmerman,

  Affiliation Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Jeffery H. Moran,

  Affiliations Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America, Public Health Laboratory, Arkansas Department of Health, Little Rock, Arkansas, United States of America

  ⨯
• William E. Fantegrossi,

  Affiliation Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Paul L. Prather

  * E-mail: PratherPaulL@uams.edu

  Affiliation Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯